GET DAILY SIGNALSINmune Bio (INMB) Q3 2026 Earnings: Cash Runway and Pipeline Updates in Focus
Key Takeaways
- INmune Bio (NASDAQ: INMB) is scheduled to report its third quarter 2026 financial results on Thursday, November 5, 2026, after the market close.
- As a pre-revenue, clinical-stage biotechnology company, the focus will be less on the top line and more on cash runway, spending discipline, and pipeline milestones.
- Consensus estimates point to a continued net loss, with analyst expectations generally in the range of roughly $0.15 to $0.18 per share for the quarter.
- Investors will be watching closely for updates on the CORDStrom program for recessive dystrophic epidermolysis bullosa (RDEB) and the XPro program for early Alzheimer's disease.
- The company's most recent quarter (Q2 2026) delivered a narrower-than-expected loss of $0.05 per share, aided by an Australian research and development tax incentive.
- Cash position and runway guidance will be a central theme, following management's prior statements that existing funds can support operations into 2027.
- For more details on INmune Bio's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional dedicated pages.
- Discover Trending AI Robots to see how AI-driven trading strategies are navigating current market conditions.
Why This Earnings Report Matters
INmune Bio is a late-stage, pre-revenue biotechnology company, so its quarterly results tend to highlight cash management and clinical progress rather than revenue. The upcoming report comes at an important time, as the company advances CORDStrom, a cell-based therapy for RDEB, toward regulatory filings in the United Kingdom, Europe, and the United States. Its XPro candidate for early Alzheimer's disease recently received Fast Track designation from the FDA. In my view, the report offers a checkpoint on whether the company can maintain its cash runway while advancing these programs, which helps gauge both financial discipline and pipeline momentum.
What Analysts Expect
Without product revenue, analyst models focus on the bottom line and operating expenses. Consensus estimates for Q3 2026 generally call for a net loss in the range of roughly $0.15 to $0.18 per share. For context, the company reported a loss of $0.05 per share in Q2 2026, beating consensus of about $0.19 to $0.20 per share, helped by an Australian research and development tax rebate and a reduced monthly cash burn of roughly $1 million to $1.5 million. In Q1 2026, INmune Bio posted a loss of $0.20 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Key metrics to watch include research and development expenses, general and administrative costs, the cash and cash equivalents balance, and any updated runway guidance. Management previously indicated its cash position was sufficient to fund operations into Q2 2027, so investors will look for confirmation that spending remains on track.
Market Sentiment Heading Into the Report
Sentiment ahead of the Q3 2026 report is driven more by pipeline news than by the financial figures themselves. INmune Bio's shares have reacted to regulatory and clinical updates, and the period since the Q2 report has included several milestones, such as progress toward a marketing authorization application filing for CORDStrom in the United Kingdom. Key risk factors include potential delays in regulatory submissions, signs of accelerating cash burn, and the possibility of future equity financing that could dilute shareholders. A bottom-line beat alone may matter less than clarity on filing timelines and partnership developments for XPro.
Looking Ahead: Key Catalysts to Watch
Beyond the Q3 print, several catalysts stand out. First is the regulatory path for CORDStrom in RDEB, where management has targeted a conditional U.K. approval filing, followed by European Medicines Agency and U.S. Biologics License Application submissions. Any confirmation or revision of these timelines will draw close attention. Second is the confirmatory Phase III trial for CORDStrom, expected to enroll roughly 40 to 45 patients over an 18-month period, with data anticipated around mid-2028. Third, the XPro program for early Alzheimer's disease continues to draw focus after receiving FDA Fast Track designation, with management evaluating strategic partnership options and late-stage trial strategies. Finally, capital allocation and runway remain central. As a company that funds operations primarily through equity sales, INmune Bio's ability to extend its cash runway while advancing multiple programs will shape both near-term sentiment and long-term execution risk.
AI Tools in Biotech Research
In my analysis, I frequently use Tickeron’s AI Screener to filter clinical-stage names and compare fundamentals or technical signals across the sector. It provides a structured way to surface peers and monitor shifting conditions without relying solely on manual review, which helps put developments like those at INmune Bio into broader context.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INMB's RSI Oscillator recovers from oversold territory
The RSI Indicator for INMB moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 26 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMB advanced for three days, in 200 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
INMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
INMB moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INMB crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for INMB entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. INMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.085) is normal, around the industry mean (3.151). P/E Ratio (-2.468) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (714.286) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapies that harness the patient's immune system to treat cancer
Industry Biotechnology
Advertisement